Jian-Chi Ma, Xiao-Hang Che, Xiao-Na Zhu, Ao-Xin Ren, Yue Hu, Cheng-Li Yang, Zhong-Tian Xu, Yu-Ting Li, Chun-Fu Wu, Jing-Yu Yang
{"title":"单剂量甲基苯丙胺通过过度DA介导的PrLGlu活性抑制作用损害小鼠的ORM检索。","authors":"Jian-Chi Ma, Xiao-Hang Che, Xiao-Na Zhu, Ao-Xin Ren, Yue Hu, Cheng-Li Yang, Zhong-Tian Xu, Yu-Ting Li, Chun-Fu Wu, Jing-Yu Yang","doi":"10.1038/s41401-024-01321-9","DOIUrl":null,"url":null,"abstract":"<p><p>Methamphetamine (METH), an abused psychostimulant, impairs cognition through prolonged or even single-dose exposure, but animal experiments have shown contradictory effects on memory deficits. In this study we investigated the effects and underlying mechanisms of single-dose METH administration on the retrieval of object recognition memory (ORM) in mice. We showed that single-dose METH administration (2 mg/kg, i.p.) significantly impaired ORM retrieval in mice. Fiber photometry recording in METH-treated mice revealed that the activity of prelimbic cortex glutamatergic neurons (PrL<sup>Glu</sup>) was significantly reduced during ORM retrieval. Chemogenetic activation of PrL<sup>Glu</sup> or glutamatergic projections from ventral CA1 to PrL (vCA1<sup>Glu</sup>-PrL) rescued ORM retrieval impairment. Fiber photometry recording revealed that dopamine (DA) levels in PrL of METH-treated mice were significantly increased, and micro-infusion of the D2 receptor (D2R) antagonist sulpiride (0.25 μg/side) into PrL rescued ORM retrieval impairment. Whole-cell recordings in brain slices containing the PrL revealed that PrL<sup>Glu</sup> intrinsic excitability and basal glutamatergic synaptic transmission were significantly reduced in METH-treated mice, and the decrease in intrinsic excitability was reversed by micro-infusion of Sulpiride into PrL in METH-treated mice. Thus, the impaired ORM retrieval caused by single-dose METH administration may be attributed to reduced PrL<sup>Glu</sup> activity, possibly due to excessive DA activity on D2R. Selective activation of PrL<sup>Glu</sup> or vCA1<sup>Glu</sup>-PrL may serve as a potential therapeutic strategy for METH-induced cognitive dysfunction.</p>","PeriodicalId":6942,"journal":{"name":"Acta Pharmacologica Sinica","volume":" ","pages":"2253-2266"},"PeriodicalIF":6.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489666/pdf/","citationCount":"0","resultStr":"{\"title\":\"Single-dose methamphetamine administration impairs ORM retrieval in mice via excessive DA-mediated inhibition of PrL<sup>Glu</sup> activity.\",\"authors\":\"Jian-Chi Ma, Xiao-Hang Che, Xiao-Na Zhu, Ao-Xin Ren, Yue Hu, Cheng-Li Yang, Zhong-Tian Xu, Yu-Ting Li, Chun-Fu Wu, Jing-Yu Yang\",\"doi\":\"10.1038/s41401-024-01321-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Methamphetamine (METH), an abused psychostimulant, impairs cognition through prolonged or even single-dose exposure, but animal experiments have shown contradictory effects on memory deficits. In this study we investigated the effects and underlying mechanisms of single-dose METH administration on the retrieval of object recognition memory (ORM) in mice. We showed that single-dose METH administration (2 mg/kg, i.p.) significantly impaired ORM retrieval in mice. Fiber photometry recording in METH-treated mice revealed that the activity of prelimbic cortex glutamatergic neurons (PrL<sup>Glu</sup>) was significantly reduced during ORM retrieval. Chemogenetic activation of PrL<sup>Glu</sup> or glutamatergic projections from ventral CA1 to PrL (vCA1<sup>Glu</sup>-PrL) rescued ORM retrieval impairment. Fiber photometry recording revealed that dopamine (DA) levels in PrL of METH-treated mice were significantly increased, and micro-infusion of the D2 receptor (D2R) antagonist sulpiride (0.25 μg/side) into PrL rescued ORM retrieval impairment. Whole-cell recordings in brain slices containing the PrL revealed that PrL<sup>Glu</sup> intrinsic excitability and basal glutamatergic synaptic transmission were significantly reduced in METH-treated mice, and the decrease in intrinsic excitability was reversed by micro-infusion of Sulpiride into PrL in METH-treated mice. Thus, the impaired ORM retrieval caused by single-dose METH administration may be attributed to reduced PrL<sup>Glu</sup> activity, possibly due to excessive DA activity on D2R. Selective activation of PrL<sup>Glu</sup> or vCA1<sup>Glu</sup>-PrL may serve as a potential therapeutic strategy for METH-induced cognitive dysfunction.</p>\",\"PeriodicalId\":6942,\"journal\":{\"name\":\"Acta Pharmacologica Sinica\",\"volume\":\" \",\"pages\":\"2253-2266\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489666/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Pharmacologica Sinica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41401-024-01321-9\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmacologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41401-024-01321-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
摘要
甲基苯丙胺(METH)是一种被滥用的精神兴奋剂,通过长期甚至单剂量接触会损害认知能力,但动物实验却显示其对记忆缺陷的影响相互矛盾。在本研究中,我们研究了单剂量 METH 对小鼠对象识别记忆(ORM)检索的影响及其内在机制。我们发现,单剂量 METH 给药(2 毫克/千克,静脉注射)会显著损害小鼠的物体识别记忆检索。METH治疗小鼠的纤维光度记录显示,在ORM检索过程中,前边缘皮层谷氨酸能神经元(PrLGlu)的活性明显降低。PrLGlu或从腹侧CA1到PrL的谷氨酸能投射(vCA1Glu-PrL)的化学激活可挽救ORM检索障碍。纤维光度记录显示,经 METH 处理的小鼠 PrL 中的多巴胺(DA)水平显著升高,而将 D2 受体(D2R)拮抗剂舒必利(0.25 μg/side)微量注入 PrL 可挽救 ORM 恢复障碍。在含有PrL的脑片中进行的全细胞记录显示,METH治疗小鼠的PrLGlu固有兴奋性和基础谷氨酸能突触传递显著降低,而在METH治疗小鼠的PrL中微量注入舒必利可逆转固有兴奋性的降低。因此,单剂量 METH 给药导致的 ORM 恢复受损可能是由于 PrLGlu 活性降低,也可能是由于 D2R 上的 DA 活性过高。选择性激活PrLGlu或vCA1Glu-PrL可能是METH诱导的认知功能障碍的一种潜在治疗策略。
Single-dose methamphetamine administration impairs ORM retrieval in mice via excessive DA-mediated inhibition of PrLGlu activity.
Methamphetamine (METH), an abused psychostimulant, impairs cognition through prolonged or even single-dose exposure, but animal experiments have shown contradictory effects on memory deficits. In this study we investigated the effects and underlying mechanisms of single-dose METH administration on the retrieval of object recognition memory (ORM) in mice. We showed that single-dose METH administration (2 mg/kg, i.p.) significantly impaired ORM retrieval in mice. Fiber photometry recording in METH-treated mice revealed that the activity of prelimbic cortex glutamatergic neurons (PrLGlu) was significantly reduced during ORM retrieval. Chemogenetic activation of PrLGlu or glutamatergic projections from ventral CA1 to PrL (vCA1Glu-PrL) rescued ORM retrieval impairment. Fiber photometry recording revealed that dopamine (DA) levels in PrL of METH-treated mice were significantly increased, and micro-infusion of the D2 receptor (D2R) antagonist sulpiride (0.25 μg/side) into PrL rescued ORM retrieval impairment. Whole-cell recordings in brain slices containing the PrL revealed that PrLGlu intrinsic excitability and basal glutamatergic synaptic transmission were significantly reduced in METH-treated mice, and the decrease in intrinsic excitability was reversed by micro-infusion of Sulpiride into PrL in METH-treated mice. Thus, the impaired ORM retrieval caused by single-dose METH administration may be attributed to reduced PrLGlu activity, possibly due to excessive DA activity on D2R. Selective activation of PrLGlu or vCA1Glu-PrL may serve as a potential therapeutic strategy for METH-induced cognitive dysfunction.
期刊介绍:
APS (Acta Pharmacologica Sinica) welcomes submissions from diverse areas of pharmacology and the life sciences. While we encourage contributions across a broad spectrum, topics of particular interest include, but are not limited to: anticancer pharmacology, cardiovascular and pulmonary pharmacology, clinical pharmacology, drug discovery, gastrointestinal and hepatic pharmacology, genitourinary, renal, and endocrine pharmacology, immunopharmacology and inflammation, molecular and cellular pharmacology, neuropharmacology, pharmaceutics, and pharmacokinetics. Join us in sharing your research and insights in pharmacology and the life sciences.